The new innovative technique against premature menopause that uses stem cells from adipose tissue and is only performed by Garavelas Medical Group.
It is a treatment for premature menopause based on the use of autologous adipose-derived stem cells (ADSCs), i.e. obtained from the fat of the person who will undergo the treatment. It is indicated in case of infertility and interruption of the menstrual cycle.
In ovary dysfunction, alteration in extra-ovarian factors, such as gonadotropins, androgen, insulin and intraovarian factors, such as growth factors and cytokines, is associated with poor quality of the oocyte.
Studies also suggest low-grade inflammation and oxidative stress are involved in the pathogenesis of ovary dysfunction.
In patients with ovary dysfunction, ovaries display persistent chronic inflammation with an enormous number of lymphocytes and macrophages, thus improper inflammation causes abnormal folliculogenesis.
Αdipose/fat tissue provides an abundant source of stromal vascular fraction (SVF) cells for immediate administration and can also give rise to a substantial number of multipotent adipose-derived stromal cells (ADSCs). Recently, both SVF and ADSCs have gained wide-ranging translational significance in regenerative medicine.
This technology in conjunction with the platelet lysate (Renovo2) technology in ovarian rejuvenation enhances the activity of the cortical part of the ovaries. The research in this field has proven that ovaries can be “reactivated” for a short period of time and that women suffering from POF or POI or even menopause may reduce their symptoms and restore the ovarian function.
It involves the removal of a small portion of fat tissue (SVF) and few ml of blood. Then, there is:
1) mechanical dissociation of the SVF,
2) centrifugation of the dissociated SVF and
3) finally, the isolation of the adipose derived stem cells from stromal vascular fraction.
In regards to ‘’Renovo2’’, the production process involves:
1) a two-step centrifugation process,
2) discard of the excess plasma volume and
3) concentrated growth factors.
The combination of the two components is performed, to form the administrated product.
This product is characterized by a high amount of regenerative growth factors such as TGF-β1, FGF, PDGF, VEGF, EGF, HGF, and other proteins with regenerative potential and thus can achieve ovary rejuvenation, through the utilization of specific signaling pathways.
This type of treatment is recommended in case of:
The procedure costs 4,950.00 €, price which also includes the anaesthetist.
For any inquiry about the treatment don’t hesitate to contact us.
We're Here To Help You
Fill in the form to receive more information about doctor and treatments